Hypocomplementemia in Primary Sjogren’s Syndrome: A Retrospective Study of 120 Treatment-Naive Chinese Patients

References

• Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for primary Sjogren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69(1):35–45. doi:10.1002/art.39859
   PubMed Web of Science ®Google Scholar
• Tsuboi H, Hagiwara S, Asashima H, et al. Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjögren’s syndrome with other sets of criteria in Japanese patients. Ann Rheum Dis. 2017;76(12):1980–1985. doi:10.1136/annrheumdis-2016-210758
   PubMed Web of Science ®Google Scholar
• Nocturne G, Virone A, Ng WF, et al. Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjögren’s syndrome. Arthritis Rheumatol. 2016;68(4):977–985. doi:10.1002/art.39518
   PubMed Web of Science ®Google Scholar
• Brodsky RA. Complement in hemolytic anemia. Blood. 2015;126(22):2459–2465. doi:10.1182/blood-2015-06-640995
   PubMed Web of Science ®Google Scholar
• Clarke AE, Weinstein A. Evaluation of the economic benefit of earlier Systemic Lupus Erythematosus (SLE) diagnosis using a Multivariate Assay Panel (MAP). Nov. 2020;2(11):629–639. doi:10.1002/acr2.11177
   Web of Science ®Google Scholar
• Merrill SA, Brodsky RA. Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Program. 2018;2018(1):371–376. doi:10.1182/asheducation-2018.1.371
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li Y, Wang L, et al. Primary Sjögren syndrome in Han Chinese: clinical and immunological characteristics of 483 patients. Medicine. 2015;94(16):e667. doi:10.1097/MD.0000000000000667
   PubMed Web of Science ®Google Scholar
• Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren’s syndrome. Semin Arthritis Rheum. 2000;29(5):296–304. doi:10.1016/s0049-0172(00)80016-5
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum. 2002;46(3):741–747. doi:10.1002/art.10221
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Yagüe J, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren’s syndrome. Rheumatology. 2005;44(1):89–94. doi:10.1093/rheumatology/keh407
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu X, Ran M, Guo X, Zhou L. The Enlargement of Abdominal Lymph Nodes Is a Characteristic of Autoimmune Liver Disease. Mediators Inflamm. 2020;2020:3631625. doi:10.1155/2020/3631625
   PubMed Web of Science ®Google Scholar
• Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest. 2013;143(3):814–824. doi:10.1378/chest.12-0741
   PubMed Web of Science ®Google Scholar
• Hewlett S, Dures E, Almeida C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Care Res. 2011;63 Suppl 11:S263–286. doi:10.1002/acr.20579
   PubMed Web of Science ®Google Scholar
• Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis. 2010;69(6):1103–1109. doi:10.1136/ard.2009.110619
   PubMed Web of Science ®Google Scholar
• Vitali C, Palombi G, Baldini C, et al. Sjögren’s Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren’s syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum. 2007;56(7):2223–2231. doi:10.1002/art.22658
   PubMed Web of Science ®Google Scholar
• Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 2005;23(5 Suppl 39):S14–18.
   PubMed Web of Science ®Google Scholar
• Jordán-González P, Gago-Piñero R. Characterization of a subset of patients with primary Sjögren’s syndrome initially presenting with C3 or C4 hypocomplementemia. Eur J Rheumatol. 2020;7(3):112–117. doi:10.5152/eurjrheum.2020.19132
   PubMed Web of Science ®Google Scholar
• Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjögren’s syndrome: a prospective cohort study. Arthritis Rheum. 2004;50(4):1262–1269. doi:10.1002/art.20176
   PubMed Web of Science ®Google Scholar
• Alunno A, Leone MC, Giacomelli R, Gerli R, Carubbi F. Lymphoma and lymphomagenesis in primary Sjögren’s syndrome. Front Med. 2018;5:102. doi:10.3389/fmed.2018.00102
   Web of Science ®Google Scholar
• Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65(6):796–803. doi:10.1136/ard.2005.041186
   PubMed Web of Science ®Google Scholar
• Solans-Laqué R, López-Hernandez A, Bosch-Gil JA, Palacios A, Campillo M, Vilardell-Tarres M. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren’s syndrome. Semin Arthritis Rheum. 2011;41(3):415–423. doi:10.1016/j.semarthrit.2011.04.006
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Isola M, Baldini C, et al. Biomarkers of lymphoma in Sjögren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun. 2014;51:75–80. doi:10.1016/j.jaut.2013.10.002
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Baldini C, Bartoloni E, et al. Anti-SSA/SSB-negative Sjögren’s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun Rev. 2015;14(11):1019–1022. doi:10.1016/j.autrev.2015.07.002
   PubMed Web of Science ®Google Scholar
• Carubbi F, Alunno A, Cipriani P, et al. A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjögren’s syndrome. Lupus. 2015;24(3):315–320. doi:10.1177/0961203314554251
   PubMed Web of Science ®Google Scholar
• Brito-Zerón P, Acar-Denizli N, Ng WF, et al. How immunological profile drives clinical phenotype of primary Sjögren’s syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). Clin Exp Rheumatol. 2018;36 Suppl 112(3):102–112.
   PubMed Web of Science ®Google Scholar
• Baldini C, Pepe P, Quartuccio L, et al. Primary Sjogren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology. 2014;53(5):839–844. doi:10.1093/rheumatology/ket427
   PubMed Web of Science ®Google Scholar
• Sandhya P, Danda D. Primary Sjögren’s syndrome in Asia: Yin and Yang? Int J Rheum Dis. 2017;20(10):1309–1312. doi:10.1111/1756-185X.13201
   PubMed Web of Science ®Google Scholar
• Brito-Zerón P, Acar-Denizli N, Ng WF, et al. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren’s syndrome. Rheumatology. 2020;59(9):2350–2359. doi:10.1093/rheumatology/kez578
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Baldini C, Bartoloni E, et al. Correlation between ESSDAI and ClinESSDAI in a real-life cohort of patients with Sjögren’s syndrome. Clin Exp Rheumatol. 2017;35(3):546–547.
   PubMed Web of Science ®Google Scholar
• Flores-Chávez A, Kostov B, Solans R, et al. Severe, life-threatening phenotype of primary Sjögren’s syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). Clin Exp Rheumatol. 2018;36 Suppl 112(3):121–129.
   PubMed Web of Science ®Google Scholar
• Priori R, Mastromanno L, Izzo R. What about glucocorticoids in primary Sjögren’s syndrome? Clin Exp Rheumatol. 2020;38 Suppl 126(4):237–244.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine. 2008;87(4):210–219. doi:10.1097/MD.0b013e318181e6af
   PubMed Web of Science ®Google Scholar
• Brito-Zerón P, Acar-Denizli N, Zeher M, et al. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients: a cross-sectional study from the big data Sjögren project consortium. Annals of the Rheumatic Diseases. 2017;76(6):1042–1050. doi:10.1136/annrheumdis-2016-209952
   PubMed Web of Science ®Google Scholar
• Maldini C, Seror R, Fain O, et al. Epidemiology of primary Sjögren’s syndrome in a French multiracial/multiethnic area. Arthritis Care Res. 2014;66(3):454–463. doi:10.1002/acr.22115
   Web of Science ®Google Scholar
• Billings M, Dye BA, Iafolla T, Baer AN, Grisius M, Alevizos I. Significance and implications of patient-reported xerostomia in Sjogren's syndrome: findings from the national institutes of health cohort. EBioMedicine. 2016;12:270–279. doi:10.1016/j.ebiom.2016.09.005
   PubMed Web of Science ®Google Scholar